Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

Authors: Kavecansky, Juraj | Nature Medicine | May 1, 2025 | PubMed abstract

Explore all publications

Back To Top